Latest Articles
05. 08. 2022
Opinion of SÚKL's Department of Clinical Trials on Medicinal Products on Ongoing Clinical Trials in Light of the COVID-19 Epidemiological Situation of 5th August 2022
In view of the coronavirus epidemiological situation that can affect ongoing clinical trials, SÚKL hereby releases statement regarding emergency measures that can apply for...
29. 07. 2022
List of reimbursed medicinal products valid as of 1.8.2022
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...
30. 06. 2022
List of reimbursed medicinal products valid as of 1.7.2022
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...
31. 05. 2022
List of reimbursed medicinal products valid as of 1.6.2022
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...
24. 05. 2022
Scientific Advice on Marketing Authorisation Issues
Upon request, the Marketing Authorisation Section of the State Institute for Drug Control (hereinafter referred to as the “Institute”) provides Scientific Advice concerning...
cz
